Loading…
Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and Ig...
Saved in:
Published in: | Antibodies (Basel) 2023-02, Vol.12 (1), p.19 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903 |
---|---|
cites | cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903 |
container_end_page | |
container_issue | 1 |
container_start_page | 19 |
container_title | Antibodies (Basel) |
container_volume | 12 |
creator | Desheva, Yulia Lerner, Anna Shvedova, Tamara Kopteva, Olga Kudar, Polina Koroleva, Irina Leontieva, Galina Suvorov, Alexander |
description | In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe (
= 17) and severe COVID-19 (
= 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r
= 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r
= 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients. |
doi_str_mv | 10.3390/antib12010019 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743462055</galeid><doaj_id>oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed</doaj_id><sourcerecordid>A743462055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</originalsourceid><addsrcrecordid>eNptks2PEyEUwCdG427WPXo1JF68zMrHAMPJNPWrycZtttorofCmZTOFlWHW9O4fLrXrujXCAQI_fvAer6peEnzBmMJvTch-RSgmGBP1pDqlWLK6aUT79NH8pDofhhtcmsRUUPW8OmFCSc6EOK1-zn0fM1rk0e3QNQxjnwcUA5rszdF5GFCOKG8ALWpkgkNf6nmKGXwoWIcWk-tFPY3LmiIf0Nz4BA4tIBnUpbhF06vl7H1NVNnJHkJR__B5g5Ym7XxYF_AOks-7F9WzzvQDnN-PZ9W3jx--Tj_Xl1efZtPJZW15o3LNGmGNcJZLKYkTrcDcGIyBCNcJahvMVi1dccqgbaRkYLi1SrSKGCkMVpidVbOD10Vzo2-T35aH6Gi8_r0Q01qblL3tQROFXUmsdBKgUQ1dKSYpMVbhRnEOrrjeHVy342oLzpbokumPpMc7wW_0Ot7p8lcNL_9QDG_uDSl-H2HIeusHC31vAsRx0FQqyrHgrSro63_QmzimUHK1pwgXVEj6l1qbEoEPXSwX271UT2RTskcx54W6-A9VuoOttzFA58v60YH6cMCmOAwJuocgCdb7MtRHZVj4V48z80D_KTr2Cwd80-8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791562672</pqid></control><display><type>article</type><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central</source><creator>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</creator><creatorcontrib>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</creatorcontrib><description>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe (
= 17) and severe COVID-19 (
= 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r
= 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r
= 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</description><identifier>ISSN: 2073-4468</identifier><identifier>EISSN: 2073-4468</identifier><identifier>DOI: 10.3390/antib12010019</identifier><identifier>PMID: 36975366</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adaptive immunity ; Amino acid metabolism ; Antibodies ; Blood pressure ; blood tests ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Enzymes ; Ethics ; Ethylenediaminetetraacetic acid ; Health aspects ; Hospitalization ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Infection ; Infections ; Laboratories ; Lymphocytes ; Measurement ; Medical research ; Neutrophils ; Oxygen saturation ; Pathogenesis ; Personal information ; Polymerase chain reaction ; Protein folding ; Proteins ; Respiration ; Respiratory diseases ; serum antibodies ; Severe acute respiratory syndrome coronavirus 2 ; severity ; Software ; Testing ; Vaccines ; Viral antibodies ; Viral infections</subject><ispartof>Antibodies (Basel), 2023-02, Vol.12 (1), p.19</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</citedby><cites>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</cites><orcidid>0000-0002-9876-6594 ; 0000-0001-9794-3520 ; 0000-0002-6649-8150 ; 0000-0002-3342-5828</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2791562672/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2791562672?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36975366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Desheva, Yulia</creatorcontrib><creatorcontrib>Lerner, Anna</creatorcontrib><creatorcontrib>Shvedova, Tamara</creatorcontrib><creatorcontrib>Kopteva, Olga</creatorcontrib><creatorcontrib>Kudar, Polina</creatorcontrib><creatorcontrib>Koroleva, Irina</creatorcontrib><creatorcontrib>Leontieva, Galina</creatorcontrib><creatorcontrib>Suvorov, Alexander</creatorcontrib><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><title>Antibodies (Basel)</title><addtitle>Antibodies (Basel)</addtitle><description>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe (
= 17) and severe COVID-19 (
= 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r
= 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r
= 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</description><subject>Adaptive immunity</subject><subject>Amino acid metabolism</subject><subject>Antibodies</subject><subject>Blood pressure</subject><subject>blood tests</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Enzymes</subject><subject>Ethics</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Health aspects</subject><subject>Hospitalization</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Infection</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Measurement</subject><subject>Medical research</subject><subject>Neutrophils</subject><subject>Oxygen saturation</subject><subject>Pathogenesis</subject><subject>Personal information</subject><subject>Polymerase chain reaction</subject><subject>Protein folding</subject><subject>Proteins</subject><subject>Respiration</subject><subject>Respiratory diseases</subject><subject>serum antibodies</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>severity</subject><subject>Software</subject><subject>Testing</subject><subject>Vaccines</subject><subject>Viral antibodies</subject><subject>Viral infections</subject><issn>2073-4468</issn><issn>2073-4468</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks2PEyEUwCdG427WPXo1JF68zMrHAMPJNPWrycZtttorofCmZTOFlWHW9O4fLrXrujXCAQI_fvAer6peEnzBmMJvTch-RSgmGBP1pDqlWLK6aUT79NH8pDofhhtcmsRUUPW8OmFCSc6EOK1-zn0fM1rk0e3QNQxjnwcUA5rszdF5GFCOKG8ALWpkgkNf6nmKGXwoWIcWk-tFPY3LmiIf0Nz4BA4tIBnUpbhF06vl7H1NVNnJHkJR__B5g5Ym7XxYF_AOks-7F9WzzvQDnN-PZ9W3jx--Tj_Xl1efZtPJZW15o3LNGmGNcJZLKYkTrcDcGIyBCNcJahvMVi1dccqgbaRkYLi1SrSKGCkMVpidVbOD10Vzo2-T35aH6Gi8_r0Q01qblL3tQROFXUmsdBKgUQ1dKSYpMVbhRnEOrrjeHVy342oLzpbokumPpMc7wW_0Ot7p8lcNL_9QDG_uDSl-H2HIeusHC31vAsRx0FQqyrHgrSro63_QmzimUHK1pwgXVEj6l1qbEoEPXSwX271UT2RTskcx54W6-A9VuoOttzFA58v60YH6cMCmOAwJuocgCdb7MtRHZVj4V48z80D_KTr2Cwd80-8</recordid><startdate>20230227</startdate><enddate>20230227</enddate><creator>Desheva, Yulia</creator><creator>Lerner, Anna</creator><creator>Shvedova, Tamara</creator><creator>Kopteva, Olga</creator><creator>Kudar, Polina</creator><creator>Koroleva, Irina</creator><creator>Leontieva, Galina</creator><creator>Suvorov, Alexander</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9876-6594</orcidid><orcidid>https://orcid.org/0000-0001-9794-3520</orcidid><orcidid>https://orcid.org/0000-0002-6649-8150</orcidid><orcidid>https://orcid.org/0000-0002-3342-5828</orcidid></search><sort><creationdate>20230227</creationdate><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><author>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adaptive immunity</topic><topic>Amino acid metabolism</topic><topic>Antibodies</topic><topic>Blood pressure</topic><topic>blood tests</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Enzymes</topic><topic>Ethics</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Health aspects</topic><topic>Hospitalization</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Infection</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Measurement</topic><topic>Medical research</topic><topic>Neutrophils</topic><topic>Oxygen saturation</topic><topic>Pathogenesis</topic><topic>Personal information</topic><topic>Polymerase chain reaction</topic><topic>Protein folding</topic><topic>Proteins</topic><topic>Respiration</topic><topic>Respiratory diseases</topic><topic>serum antibodies</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>severity</topic><topic>Software</topic><topic>Testing</topic><topic>Vaccines</topic><topic>Viral antibodies</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Desheva, Yulia</creatorcontrib><creatorcontrib>Lerner, Anna</creatorcontrib><creatorcontrib>Shvedova, Tamara</creatorcontrib><creatorcontrib>Kopteva, Olga</creatorcontrib><creatorcontrib>Kudar, Polina</creatorcontrib><creatorcontrib>Koroleva, Irina</creatorcontrib><creatorcontrib>Leontieva, Galina</creatorcontrib><creatorcontrib>Suvorov, Alexander</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Antibodies (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Desheva, Yulia</au><au>Lerner, Anna</au><au>Shvedova, Tamara</au><au>Kopteva, Olga</au><au>Kudar, Polina</au><au>Koroleva, Irina</au><au>Leontieva, Galina</au><au>Suvorov, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</atitle><jtitle>Antibodies (Basel)</jtitle><addtitle>Antibodies (Basel)</addtitle><date>2023-02-27</date><risdate>2023</risdate><volume>12</volume><issue>1</issue><spage>19</spage><pages>19-</pages><issn>2073-4468</issn><eissn>2073-4468</eissn><abstract>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe (
= 17) and severe COVID-19 (
= 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r
= 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r
= 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36975366</pmid><doi>10.3390/antib12010019</doi><orcidid>https://orcid.org/0000-0002-9876-6594</orcidid><orcidid>https://orcid.org/0000-0001-9794-3520</orcidid><orcidid>https://orcid.org/0000-0002-6649-8150</orcidid><orcidid>https://orcid.org/0000-0002-3342-5828</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2073-4468 |
ispartof | Antibodies (Basel), 2023-02, Vol.12 (1), p.19 |
issn | 2073-4468 2073-4468 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed |
source | Access via ProQuest (Open Access); PubMed Central |
subjects | Adaptive immunity Amino acid metabolism Antibodies Blood pressure blood tests Coronaviruses COVID-19 COVID-19 vaccines Enzymes Ethics Ethylenediaminetetraacetic acid Health aspects Hospitalization Immunoglobulin A Immunoglobulin G Immunoglobulin M Infection Infections Laboratories Lymphocytes Measurement Medical research Neutrophils Oxygen saturation Pathogenesis Personal information Polymerase chain reaction Protein folding Proteins Respiration Respiratory diseases serum antibodies Severe acute respiratory syndrome coronavirus 2 severity Software Testing Vaccines Viral antibodies Viral infections |
title | Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20Study%20Results%20on%20Antibodies%20to%20the%20S-%20and%20N-Proteins%20of%20SARS-CoV-2%20in%20Paired%20Sera%20from%20COVID-19%20Patients%20with%20Varying%20Severity&rft.jtitle=Antibodies%20(Basel)&rft.au=Desheva,%20Yulia&rft.date=2023-02-27&rft.volume=12&rft.issue=1&rft.spage=19&rft.pages=19-&rft.issn=2073-4468&rft.eissn=2073-4468&rft_id=info:doi/10.3390/antib12010019&rft_dat=%3Cgale_doaj_%3EA743462055%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2791562672&rft_id=info:pmid/36975366&rft_galeid=A743462055&rfr_iscdi=true |